Five-Day Changes in Biomarkers of Exposure Among Adult Smokers After Completely Switching From Combustible Cigarettes to a Nicotine-Salt Pod System.

Plain-language guide to PMID 31688930 (2020): open-label randomized controlled trial of Therapeutic nicotine (patch, non-peptide).

Key Facts

PMID: 31688930
Journal: Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco
Year: 2020
Study type: Randomized Controlled Trial
Authors: Jay J et al. (5 authors)
DOI: 10.1093/ntr/ntz206

What This Study Did, in Plain Language

What Was Tested

This randomized controlled trial looks at Therapeutic nicotine (patch, non-peptide).

A randomized, open-label, parallel-cohort, confinement study of healthy adult smokers, naive to NSPS use, was conducted.

Participants (N = 90) were randomized to six cohorts (n = 15 each): exclusive ad libitum use of NSPS (four flavors: Virginia Tobacco, Mint, Mango, Creme), continuation of usual-brand cigarette smoking, or cigarette abstinence.

Total nicotine equivalents and BoE (NNN, NNAL, 3-HPMA, MHBMA, S-PMA, HMPMA, CEMA, 1-OHP, and COHb) were measured.

Who Took Part

By PubMed's age tags, the people studied were young adults, adults and middle-aged adults, both men and women.

How the Study Was Run

In design terms this was a randomized, open-label and parallel-group study.

Because people in this Therapeutic nicotine (patch, non-peptide) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Being open-label, the Therapeutic nicotine (patch, non-peptide) study did not mask who received what.

The Therapeutic nicotine (patch, non-peptide) group and the comparison group ran side by side rather than switching.

What Was Measured

PubMed files the paper under topics including Carcinogens, Cigarette Smoking, Electronic Nicotine Delivery Systems, Inhalation Exposure, Nicotine, Salts and San Francisco.

What This Means in Plain Language

The paper is a randomized, open-label and parallel-group study of Therapeutic nicotine (patch, non-peptide).

The abstract goes on to report its results in about 8 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2020 (Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco), a journal based in England.

More context: the Therapeutic nicotine (patch, non-peptide) compound page, all human trials.

Our Notes on the Compound

Therapeutic nicotine (patch, non-peptide): Pure nicotine as a signaling tool, separated from smoking and vaping.

Therapeutic nicotine (patch, non-peptide) in the library

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.